AGYTFAllergy Therapeutics plc
Nov 10, 2026 — Strategic Capital Raise / Offering Announcement
Chart by TradingViewThe schedule
- Tue10Nov
High probability of an equity offering or dilutive financing event to secure runway for ongoing clinical trials.
- Mon15Feb
Anticipated readout or regulatory guidance regarding the company's core allergy immunotherapy (e.g., Peanut or Grass MATA MPL) pipeline.
- Thu15Apr
Full year 2026 financial report detailing operational runway, R&D expenditures, and commercial traction.
Past
- Thu24Sep
Actual outcome: Bear · $0.15 at outcome
Stock fell 100.0% from event to outcome date, aligning with the bear trajectory.
Expected H1 2026 earnings release, focusing on cash burn reduction and revenue growth sustainability.